AI-Powered trial asks: does adding a second drug cut heart failure risk?
Knowledge-focused
Not yet recruiting
This study uses computer simulations to compare two treatment strategies for people with chronic kidney disease and type 2 diabetes. Researchers will model whether adding empagliflozin to finerenone reduces heart failure, hospitalizations, and cardiovascular death more than finer…
Sponsor: Aeterna Medical Solutions SL • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC